AstraZeneca shares soared to unprecedented levels on Tuesday, eclipsing their previous September 2024 high and reinforcing the company as the largest UK-listed entity by market capitalization. The favorable response from investors came after a series of impressive earnings and a significant U.S. policy development.
By 0832 GMT, shares jumped by 2.5%, reaching a peak of 134.6 pounds, which valued the company at close to 210 billion pounds ($282 billion). This surge also fueled a broader upswing in the FTSE index, which rose 1.1% amid encouraging UK labor market data and speculation regarding a possible rate cut from the Bank of England next month.
AstraZeneca's recent achievements were bolstered by a quarterly earnings report that exceeded forecasts and an October agreement on U.S. drug pricing, easing investor fears about regulatory uncertainties. The U.S. market continues to be crucial for the company, accounting for over 40% of its total sales.
Market observers point out that the combination of robust financial results and diminished policy risks has revitalized confidence among investors, exerting significant upward pressure on the stock. This record-high surge also underscores increasing optimism regarding the UK pharmaceutical sector in the face of global demand for innovative therapies.
A drone strike near Dubai Airport hit a fuel tank and caused a large fire. Flights were temporarily
Donald Trump says the US will focus on ending the Iran conflict before dealing with Cuba, even as ta
Federal government signs landmark agreements with Musqueam Nation, recognizing Aboriginal rights whi
Canada’s labour market faltered with a sharp drop in employment and higher unemployment, marking the
